PT  - JOURNAL ARTICLE
AU  - Chen Sun
AU  - Chong Lu
AU  - Yongjian Zhang
AU  - Ling Wang
AU  - Zhenjian Ge
AU  - Zhenyu Wen
AU  - Wenkang Chen
AU  - Yingqi Li
AU  - Yutong Wu
AU  - Shengjie Lin
AU  - Pengwu Zhang
AU  - Wuping Wang
AU  - Siwei Chen
AU  - Huimei Zhou
AU  - Xutai Li
AU  - Shaobin Wang
AU  - Yong Xia
AU  - Wei Li
AU  - Wei Lan
AU  - Yongjiang Cai
AU  - Ling Ji
AU  - Haibo Wang
AU  - Yongqing Lai
TI  - Evaluation of the MCED value of YiDiXie<sup>™</sup>-HS and YiDiXie<sup>™</sup>-SS
AID  - 10.1101/2024.03.11.24303683
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.11.24303683
4099  - http://medrxiv.org/content/early/2024/03/14/2024.03.11.24303683.short
4100  - http://medrxiv.org/content/early/2024/03/14/2024.03.11.24303683.full
AB  - Background Cancer is a serious threat to the whole of humanity. The Multi-Cancer Early Detection (MCED) test is expected to solve the problem of “Universal cancer screening”. The purpose of this study is to evaluate the screening performance of two MCED tests, YiDiXie™-HS and YiDiXie™-SS, in multiple cancer types.Patients and methods 11094 subjects were finally included in this study (the malignant tumor group, n = 4405; the normal control group, n = 6689). The malignant tumor group included all solid and hematological malignant tumor types covered in “China cancer registry annual report” by the National Cancer Center of China. The sensitivity and specificity of YiDiXie™-HS and YiDiXie™-SS were evaluated, respectively.Results The overall sensitivity of YiDiXie™-HS for different cancer types and stages was 90.1% (89.2% - 90.9%; 3971/4405), and its specificity was 89.7% (89.0% - 90.4%; 6002/6689). Its sensitivity increases with clinical stage: stage I, 85.6% (83.9% - 87.1%); stage II, 91.4% (89.6% - 93.0%); stage III, 93.9% (92.0% - 95.4%); and stage IV, 98.4% (96.9% - 99.2%). The overall sensitivity of YiDiXie™-SS for different cancer types and stages was 99.1% (98.8% - 99.3%; 4365/4405), and its specificity was 65.2% (64.0% - 66.3%; 4358/6689). Its sensitivity was basically comparable in each clinical stage: stage I, 98.6% (98.0% - 99.1%); stage II, 99.5% (98.9% - 99.8%); stage III, 99.5% (98.6% - 99.8%); stage IV, 99.8% (98.9% - 100.0%).Conclusion YiDiXie™-HS has a high sensitivity in all clinical stages of all cancer types and can be a powerful complement to existing cancer screening tests. YiDiXie™-SS has an extremely high sensitivity in all clinical stages of all cancer types and is expected to solve the world problem of “Universal cancer screening”.Clinical trial number ChiCTR2200066840.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript.